Vista antagonist and methods of use

Patent metadata

Field	Value
Publication number	US-12064463-B2
Application number	US-202117186199-A
Country	US
Kind code	B2
Filing date	Feb 26, 2021
Priority date	Jun 22, 2012
Publication date	Aug 20, 2024
Grant date	Aug 20, 2024

Abstract

The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

First claim

What is claimed is:

1. An isolated VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO: 1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), or a multimer or conjugate thereof.

2. A VISTA antagonist comprising a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), except that one amino acid residue thereof is modified by a modification selected from the group consisting of PEGylation, acetylation, and XTEN.

3. A VISTA antagonist comprising a fusion protein which comprises a peptide which is identical to the amino acid sequence of SEQ ID NO:1 (Ser-Ser-Ala-Cys-Asp-Trp-Ile-Lys-Arg-Ser-Cys-His), wherein said peptide is directly or indirectly conjugated to albumin or an immunoglobulin constant or Fc region.

4. The fusion protein of claim 3 , wherein said immunoglobulin Fc region comprises a human IgG1, IgG2, IgG3 or IgG4 constant or Fc region.

5. The fusion protein of claim 3 , wherein said immunoglobulin constant or Fc region comprises a human IgG1 constant or Fc region.

6. A pharmaceutical composition comprising an effective amount of a VISTA antagonist according to claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising an effective amount of a VISTA antagonist according to claim 1 and a pharmaceutically acceptable carrier and another active agent.

8. A pharmaceutical composition comprising an effective amount of a VISTA antagonist according to claim 2 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising an effective amount of a VISTA antagonist according to claim 3 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising an effective amount of a VISTA antagonist according to claim 4 and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising an effective amount of a VISTA antagonist according to claim 5 and a pharmaceutically acceptable carrier.

Assignees

• King S College London
• Dartmouth College

Inventors

• Noelle Randolph J
• Ceeraz Sabrina
• Lemercier Isabelle
• Nowak Elizabeth
• Lines Janet
• Wang Li
• Spaller Mark

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• G01N33/566

  using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds} · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/74

  Inducing cell proliferation · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title